{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-198578","form_type":"8-K","ticker":"APLS","cik":"0001492422","company_name":"Apellis Pharmaceuticals, Inc.","filed_at":"2023-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.071436+00:00","generated_at":"2026-06-12T21:57:12.165472+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Apellis Q2 revenue $95.0M; SYFOVRE sales $67.3M; net loss $122.0M","bullets":["Total US net product revenue of $89.6M: SYFOVRE $67.3M (GA), EMPAVELI $22.3M (PNH).","Net loss of $122.0M improved from $156.0M loss in Q2 2022; cash $616.3M.","SYFOVRE reduced nonsubfoveal GA lesion growth up to 45% at Months 24-30 in GALE extension.","Investigation of rare retinal vasculitis events found no drug product or manufacturing issues.","R&D expenses $95.7M, G&A $111.4M; company funded into Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-198578","json":"https://secwatch.observer/filing/0001193125-23-198578.json","markdown":"https://secwatch.observer/filing/0001193125-23-198578.md","text":"https://secwatch.observer/filing/0001193125-23-198578.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523198578/0001193125-23-198578-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523198578/d532845d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T21:57:12.165472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c2d5bad3ce127f3259879360ef9631860c15e235","claim":"Apellis Pharmaceuticals, Inc. reported the second quarter 2023 results: revenue $95.0 million.","evidence_excerpt":"total revenue was $95.0 million for the second quarter of 2023, which consisted of $22.3 million of U.S. net product revenue of EMPAVELI, $67.3 million of U.S. net product revenue of SYFOVRE, and additional licensing and other revenue under the Sobi collaboration.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523198578/0001193125-23-198578-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter 2023"},{"label":"Revenue","value":"$95.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}